Glenmark Life Sciences
Glenmark Life Sciences, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions, including North America, Europe, and Asia. Founded in 2013, the company has rapidly established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations, particularly in the therapeutic areas of cardiology, diabetes, and central nervous system disorders. With a commitment to quality and innovation, Glenmark Life Sciences offers a diverse portfolio of products that cater to both generic and branded markets. The company is recognised for its robust research and development capabilities, which have led to significant milestones in API production. As a subsidiary of Glenmark Pharmaceuticals, it has garnered a strong market position, contributing to the global healthcare landscape with its high-quality, cost-effective solutions.
DitchCarbon Score
How does Glenmark Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Life Sciences's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glenmark Life Sciences's reported carbon emissions
In 2024, Glenmark Life Sciences reported total carbon emissions of approximately 667,131,590 kg CO2e for Scope 1 and 59,703,280 kg CO2e for Scope 2. This reflects a significant commitment to transparency in their emissions reporting, with both scopes disclosed. In 2023, the company recorded emissions of about 12,798,000 kg CO2e for Scope 1 and 50,407,400 kg CO2e for Scope 2, indicating a substantial increase in Scope 1 emissions year-on-year. Glenmark Life Sciences operates as a current subsidiary of Alivus Life Sciences Limited, which influences its emissions data. The emissions data for 2024 and 2023 is cascaded from Alivus Life Sciences Limited, ensuring a comprehensive view of their carbon footprint. Despite the detailed emissions reporting, Glenmark Life Sciences has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of Scope 3 emissions data suggests that the company may be focusing on direct and indirect emissions from their operations and energy use, but further initiatives could enhance their overall climate strategy. Overall, Glenmark Life Sciences is actively engaging in emissions reporting, but there remains an opportunity to establish clear reduction targets to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 26,879,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 49,900,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Life Sciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
